GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies

Current Opinion in Investigational Drugs

Volumn 10, Issue 6, 2009, Pages 588-596

  Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AFUTUZUMAB; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; GA 101; PREDNISONE; PROTEIN BCL 2; R 7159; RITUXIMAB; RO 5072759; UNCLASSIFIED DRUG; VINCRISTINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CELL KILLING; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GENETIC ENGINEERING; HERPES LABIALIS; HUMAN; HYPERTENSION; HYPOTENSION; INJECTION SITE REACTION; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR REGRESSION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG EVALUATION, PRECLINICAL; GLYCOSYLATION; HUMANS; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; MICE; PATENTS AS TOPIC; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67650657179     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. 411165 Signaling events involved in anti-CD20-induced apoptosis of malignant human B-cells. Shan D, Ledbetter JA, Press OW CANCER IMMUNOL IMMUNOTHER 2000 48 12 673-683
2. 413667 Expert cancer researcher named ILEX vice president, global cancer research. ILEX Oncology Inc PRESS RELEASE 2001 June 26
3. 423535 Schering AG: Campath successful in trial for treatment of T-PLL. Schering AG PRESS RELEASE 2001 September 28
4. 429396 Characterization of a human B lymphocyte-specifc antigen. Stashenko P, Nadler LM, Hardy R, Schlossman SF J IMMUNOL 1980 125 4 1678-1685
5. 441354 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. Coiffer B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F et al N ENGL J MED 2002 346 4 235-242
6. 447273 Chemotherapy sensitization by rituximab: Experimental and clinical evidence. Wilson WH SEMIN ONCOL 2000 27 6 Suppl 12 30-36
7. 639819 Initial safety and effcacy results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in non-Hodgkin's lymphoma. Morschhauser F, Leonard JP, Coiffer B, Petillon M-O, Coleman M, Bahkti A, Sapra P, Teoh N, Wegener WA, Horak ID, Goldenberg DM BLOOD 2005 106 11 Abs 2428
8. 652886 FDA approves Rituxan - The frst targeted B-cell therapy for treatment of moderate-to-severe rheumatoid arthritis. Genentech Inc PRESS RELEASE 2006 February 28
9. 720489 FDA approves two new indications for Rituxan in patients with non-Hodgkin's lymphoma. Genentech Inc PRESS RELEASE 2006 September 29
10. 748106 Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modifed elbow hinge for enhanced ADCC and superior apoptosis induction. Umana P, Moessner E, Bruenker P, Unsin G, Puentener U, Suter T, Grau R, Schmidt C, Gerdes C, Nopora A, Patre M et al BLOOD 2006 108 11 Abs 229
11. 770103 The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD et al BLOOD 2007 109 5 1857-1861
12. 777376 GA101: A humanized third generation type II CD20 antibody with superior cell death induction and glycoengineered Fc region for enhanced ADCC. Umana P, Moessner E, Bruenker P, Unsin G, Puentener U, Grau R, Schmidt C, Gerdes C, Nopora A, Patre M, Moser S et al AM ASSOC CANCER RES ANN MEET 2007 48 Abs 4186
13. 784950 Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM CLIN CANCER RES 2004 10 8 2868-2878
14. 829127 NCT00517530: A dose-escalating study of R7159 in patients with CD20+ malignant disease. Hoffmann-La Roche CLINICALTRIALS.GOV 2007 September 18
15. 841942 Novel third generation humanized type II CD20 antibody with superior direct cell death induction and glycoengineered Fc region for enhanced ADCC induction. Umana P, Moessner E, Bruenker P, Unsin G, Suter T, Grau R, Puentener U, Schmidt C, Gerdes C, Napora A, Patre M et al AACR-NCI-EORTC INT CONGRESS 2007 19 Abs A56
16. 859997 Interim results of a phase I/II study of ocrelizumab, a new humanised anti-CD20 antibody in patients with relapsed/refractory follicular non-Hodgkin's lymphoma. Morschhauser F, Marlton P, Vitolo U, Linden O, Seymour J, Crump M, Coiffer B, Pulsoni A, Belch A, Lerch E, Kimby E et al BLOOD 2007 110 11 Abs 645
17. 860010 GA101, a novel humanized type II CD20 antibody with glycoengineered Fc and enhanced cell death induction, exhibits superior anti-tumor effcacy and superior tissue B cell depletion in vivo. Umana P, Ekkehard M, Peter B, Gabriele K, Ursula P, Suter T, Grau R, Schmidt C, Herter S, Gerdes C, Nopora A et al BLOOD 2007 110 11 Abs 2348
18. 872719 Roche annual report 2007 - Business report. Roche Holding AG ANNUAL REPORT 2008 January 30
19. 873898 NCT00546793: Phase I/II study of subcutaneously administered veltuzumab (HA20) in NHL and CLL. Immunomedics Inc CLINICALTRIALS.GOV 2008
20. 893196 The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, Parren PW et al J IMMUNOL 2006 177 1 362-371
21. 896777 GA101, a novel therapeutic type II CD20 antibody with outstanding effcacy and clear superiority in subcutaneous non-Hodgkin lymphoma xenograft models. Friess T, Herting F, Bauer S, Nopora A, Van Puijenbroek E, Gerdes C, Schuell C, Umana P, Klein C AM ASSOC CANCER RES ANN MEET 2008 99 Abs 3982
22. 896784 Contribution of enhanced ADCC to superior in vivo effcacy of a novel type II humanized, third generation CD20 antibody (GA101) in NHL xenograft models. Nopora A, Preiss S, Nicolini V, Roemmele M, Van Puijenbroek E, Freytag O, Patre M, Bauer S, Klein C, Umana P, Gerdes CA AM ASSOC CANCER RES ANN MEET 2008 99 Abs 3991
23. 899601 Diffuse large B-cell lymphoma. Hunt KE, Reichard KK ARCH PATHOL LAB MED 2008 132 1 118-124
24. 899662 Monoclonal antibodies in the treatment of autoimmune cytopenias. Robak T EUR J HAEMATOL 2004 72 2 79-88
25. 899663 Novel monoclonal antibodies for the treatment of chronic lymphocytic leukaemia. Robak T CURR CANCER DRUG TARGETS 2008 8 2 156-171
26. 899672 Antibody specifcity controls in vivo effector mechanisms of anti-CD20 reagents. Cragg MS, Glennie MJ BLOOD 2004 103 7 2738-2743
27. 899679 The biology of human natural killer cells. Whiteside TL, Herberman RB ANN IST SUPER SANITA 1990 26 3-4 335-348
28. 899716 Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ J CLIN ONCOL 2006 24 19 3121-3127
29. 899746 The Leukemia & Lymphoma Society: Chronic lymphocytic leukaemia. The Leukemia & Lymphoma Society INTERNET SITE 2007 September 09
30. 900095 Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P et al J CLIN ONCOL 2005 23 18 4117-4126
31. 903315 NCT00576758: A dose-escalating study of R7159 monotherapy in patients with CD20+ malignant disease Hoffmann-La Roche CLINICALTRIALS. GOV 2008
32. 912498 Laboratory and clinical studies of high anti-lymphoma potency with anti-CD20 veltuzumab and differentiation from rituximab. Goldenberg DM, Chang C, Rossi EA, Cardillo TM, Wegener WA, Teoh N, Leonard JP, Fayad LE, Coiffer B, Morschhauser F J CLIN ONCOL 2008 26 15S Abs 3043
33. 912802 Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Robak T CURR OPIN MOL THER 2008 10 3 294-309
34. 947337 American Cancer Society. Cancer facts & fgures 2008. American Cancer Society Inc COMPANY PUBLICATION 2008 February 28
35. 948251 Genentech agrees to codevelop Glycart's afutuzumab Genentech Inc PRESS RELEASE 2008 October 03
36. 952567 GA101, a therapeutic glycoengineered CD20 antibody recognizing a type II epitope mediates outstanding anti-tumor effcacy in non-Hodgkin's lymphoma xenograft models and superior B-cell depletion. Klein C, Herting F, Friess T, Gerdes C, Nopora A, Bauer S, Grau R, Moessner E, DalPorto J, Umana P EJC SUPPL 2008 6 12 Abs 504
37. 954882 Ocrelizumab, a humanized monoclonal antibody against CD20 for infammatory disorders and B-cell malignancies. Hutas G CURR OPIN INVEST DRUGS 2008 9 11 1206-1215
38. 957962 Biogen Idec elects to participate with Genentech in the development and commercialization of a next generation anti-CD20 molecule. Biogen Idec Inc PRESS RELEASE 2008 October 30
39. 967210 Compared antitumor activity of GA101 and rituximab against the human RL follicular lymphoma xenografts in SCID beige mice. Dalle S, Reslan L, Manquat SB, Herting F, Klein C, Umana P, Dumontet C BLOOD 2008 112 11 Abs 1585
40. 968146 A phase I/II study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease. Salles GA, Morschhauser F, Cartron G, Lamy T, Milpied NJ, Thieblemont C, Tilly H, Birkett J, Burgess M BLOOD 2008 112 11 Abs 234